After seeing a dramatic increase in the development and use of immunotherapy and
precision medicine over the past few decades, oncological care now embraces the start of …

Chimeric antigen receptor T (CAR‐T) therapy has emerged as a revolutionary new pillar in
cancer care, particularly in relapsed/refractory (r/r) B‐cell malignancies. Following …

Although chimeric antigen receptor (CAR) T cell therapy (CAR-T) has altered the treatment
landscape for relapsed/refractory B cell malignancies and multiple myeloma, only a minority …

The search for innovative anti-cancer drugs remains a challenge. Over the past three
decades, antibodies have emerged as an essential asset in successful cancer therapy. The …

The advent of chimeric antigen receptor T cells (CAR-T cells) has made a tremendous
revolution in the era of cancer immunotherapy, so that since 2017 eight CAR-T cell products …

The emergence of chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the
treatment of hematologic malignancies, including multiple myeloma (MM). Two BCMA …

Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful
personalized therapeutic agents showing dramatic preclinical and clinical results …

Chimeric antigen receptor T (CAR-T) cell therapy, as an adoptive immunotherapy, is playing
an increasingly important role in the treatment of malignant tumors. CAR-T cells are referred …

Cancer immunotherapies include monoclonal antibodies, cytokines, oncolytic viruses,
cellular therapies, and other biological and synthetic immunomodulators. These are …

Background: Chimeric antigen receptor T cells treatment targeting B cell maturation antigen
(BCMA) is an emerging treatment option for relapsed/refractory multiple myeloma (RRMM) …